Conference Coverage

Tildrakizumab shows positive effects in active psoriatic arthritis


 

REPORTING FROM EULAR 2019 CONGRESS

SOURCE: Mease PJ et al. Ann Rheum Dis. Jun 2019;78(Suppl 2):77-9. Abstract LB0002, doi: 10.1136/annrheumdis-2019-eular.8669

Pages

Recommended Reading

Active psoriatic arthritis, ankylosing spondylitis linked to increase in adverse pregnancy outcomes
MDedge Rheumatology
Carotid ultrasound may aid cardiovascular risk stratification of patients with psoriatic disease
MDedge Rheumatology
Ixekizumab surpasses adalimumab in PsA head-to-head study
MDedge Rheumatology
Obesity might be targetable driver of psoriatic arthritis progression
MDedge Rheumatology
Systemic psoriasis treatments less often prescribed in elderly with psoriasis, despite comparable response rates
MDedge Rheumatology
Infections linked with transition to psoriatic arthritis
MDedge Rheumatology
EULAR keeps csDMARDs as top PsA drugs
MDedge Rheumatology
Unacceptable pain despite inflammation control commonly occurs in PsA patients
MDedge Rheumatology
Flu vaccine succeeds in TNF inhibitor users
MDedge Rheumatology
Ixekizumab boosts quality of life in genital psoriasis
MDedge Rheumatology